A leading international family entertainment and media enterprise, Agora Holdings, Inc. (OTC: AGHI) offers TV, studio entertainment, interactive media, media networks, and consumer products. Through its wholly-owned subsidiary, Geegle Media, the company aims to fill the needs of social media, TV, data storage software, and other optimizing solutions.

In July 2015, Agora Holdings, through Geegle Media, developed GeegleTV, which combines radio, news, TV on demand, newspapers, sports, and kids content for an exciting interactive experience. GeegleTV has customizable services for a wide range of users. For example, freelancers and content producers have their own channel, which delivers helpful, usable content. GeegleTV also attracts real estate brokers to their very own channel. This channel allows brokers to market their properties in a virtual experience accessible to clients from any computer.

That same month, the company announced its software integration alliance with YouTube, which has the largest collection of media content in the world. This integration allows GeegleTV to curate even more content than previously available. GeegleTV has also built software that filters third party content for better quality to its users. GeegleTV aims to deliver high-quality content from around the world that is easily accessible and personalized to the end-user.

In a news release, Agora Holdings CEO Dan Terziev stated, “”The web has become so vast that the trend now is to go back, manage and shrink it, rather than adding content. We sort it out and curate to taste.”

The software integration between GeegleTV and YouTube continues. However, creating a better way of caching sourced content on the former’s website is in the works. The next step is for GeegleTV to create a mode of receiving YouTube content which abides by its licensing agreement.

Agora Holdings intends to provide the “world’s best entertainment and online experiences.” By managing and improving its current projects, including 1000salads and Real TV, the company will look to continue its steady ascent into the media-entertainment industry.

For more information, visit www.agoraholdingsinc.com

Let us hear your thoughts: Agora Holdings, Inc. Message Board

Thought to have originated in Africa, the acquired immunodeficiency syndrome (AIDS) has undoubtedly become a scourge of the continent, particularly south of the Sahara. According to AVERT, the U.K.-based international charity, in sub-Saharan Africa, 24.7 million people, or about 4.7% of the continental population, were living with the human immunodeficiency virus (HIV) in 2013, the last year for which data is available. Over one million of those individuals have died every year since. South Africa, with 5.9 million, has the highest number of infected persons. Swaziland’s HIV infection rate of 27.4% (2013) is the highest worldwide. In Nigeria, although the HIV rate is comparably low (3.2%), this translates into 3.2 million persons because of the country’s huge population. Thus, the recently concluded 90-day bridging trial of HIV-positive patients in Nigeria by Immune Therapeutics, Inc. (OTCQB: IMUN) was most welcome.

In January 2016, on completion of the bridging trial, the company announced it had submitted data to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC). The company expects that the Nigerian authorities will approve Lodonal™ as a treatment for those with compromised immune systems, such as occurs in HIV infection. The bridging study sought to examine the effectiveness of Lodonal as a treatment to stabilize and improve CD4 count. The parameters of stabilization were set at 10% either side of the mean. A 25% increase in CD4 count, in the infected group over the control group, was set as the target for Lodonal’s effectiveness in improving CD4 cell count.

A CD4 count is a lab test that measures the number of CD4 T lymphocytes (CD4 cells) in a sample of blood. In people with HIV, it is the most important laboratory indicator of how well the immune system is working and the strongest predictor of HIV progression. CD4 cells (often called T-cells or T-helper cells) are a type of white blood cells that play a major role in protecting your body from infection. They send signals to activate your body’s immune response when they detect invasion from viruses or bacteria. The CD4 count of a healthy individual typically ranges from 500 cells per cubic millimeter to 1,200 cells per cubic millimeter. When the count falls below 200 cells per cubic millimeter, it may indicate that a person living with HIV has progressed to stage 3 infection (AIDS).

The progression of an HIV infection typically follows three stages. Acute HIV infection is the first stage. It is characterized by symptoms similar to a very bad attack of influenza and usually occurs some two to four weeks after contraction of the virus. Also referred to as acute retroviral syndrome (ARS) or primary HIV infection, these flu-like symptoms are signs of the body’s natural response to the HIV infection.

After the acute stage of HIV infection, the disease moves into a stage called the clinical latency stage, during which the virus continues to live and reproduce at very low levels but produces no or very mild symptoms. This period is also referred to as the asymptomatic HIV infection or chronic HIV infection stage. AIDS is the third and final stage, when the immune system has been so greatly compromised that the body can no longer ward off opportunistic infections. An individual is also considered to have progressed to AIDS if he or she develops one or more opportunistic illnesses, regardless of the CD4 count. Without treatment, people who progress to AIDS typically survive about three years. If a dangerous opportunistic illness is contracted, life-expectancy without treatment falls to about one year.

Immune Therapeutics, Inc. is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN), known internationally as Lodonal, and Methionine-Enkephalin (MENK). Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF. These efforts were pioneered by leading immunologists, including Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, Dr. Jill Smith, Patricia McLaughlin, and Dr. Jaquelyn McCandless.

Learn more by visiting www.immunetherapeutics.com

Let us hear your thoughts: Immune Therapeutics, Inc. Message Board

Earlier this week, Star Mountain Resources, Inc. (OTC: SMRS) filed a form 8-K with the U.S. Securities and Exchange Commission regarding a promissory note issued by its wholly-owned subsidiary, St. Lawrence Zinc Company, LLC, in the aggregate principal amount of $500,000 payable to the Development Authority of the North Country, a New York public benefit trust. Payments of accrued interest associated with the loan are set to commence on April 1, 2016. Repayment of the principal amount, as well as all accrued and unpaid interest, is due on or before April 1, 2017. In the filing, the company states that the proceeds of this loan will be used for general working capital purposes.

By strengthening its cash position, Star Mountain will look to capitalize on the recent rise in zinc prices. As previously discussed in an article on QualityStocks (http://dtn.fm/DI2Od), zinc was hampered last year, in large part, by China’s economic slowdown, which seriously impacted global demand. However, with global mine depletion and severe production cutbacks tightening supply, prices have rebounded strongly. Year to date, the mineral has rose more than 27 percent since bottoming in early January (http://dtn.fm/8E7hd), closing at $1,869.75 on March 20, and zinc has shown no signs of slowing down. In fact, according to analysts with Goldman Sachs, zinc currently has “the strongest bull case” of the metals market (http://dtn.fm/5Bg0O).

Star Mountain originally entered the zinc mining business last November, when, despite slumping commodity prices, the company’s management team closed on the acquisition of Northern Zinc and Balmat Holding Corporation, including St. Lawrence Zinc Company, LLC and its mining operations in the Balmat mining district of St. Lawrence County, New York. This move demonstrated the foresight of the company’s management team, as outlined in an article on the QualityStocks blog (http://dtn.fm/jlP9k).

“We continue to evaluate the current zinc market and the best strategy to move forward with a production plan and schedule,” Joe Marchal, chief executive officer of Star Mountain, stated in a recent news release.

In February, the company’s investors received more positive news when an Industry Guide 7 (IG7) Mineral Reserve Report for the Balmat mine property supported Star Mountain’s initial reserve estimate, reflecting roughly 585,000 tons of proven and probable reserves with a 9.2 percent grade zinc that could generate an estimated $80.8 million in revenue over an initial 2.5-year mine plan. The report also reaffirmed the company’s confidence that the property could sustain production as part of a larger, 8.5-year mine plan moving forward.

“We believe the findings in the IG7 report are very positive and reaffirm our confidence that the geological and engineering conditions reflected in the long production history of the Balmat mining operation can be sustained well into the future beyond the initial 2.5-year plan,” continued Marchal.

Having previously announced intentions to proceed with zinc recovery in a timely manner, Star Mountain’s recent efforts to strengthen its short-term cash position should come as no surprise. With zinc already climbing above Goldman Sachs’ 12-month target price and recent news that China is expected to eliminate an estimated 500,000 metric tons of high cost zinc smelting output capacity by the end of the year (http://dtn.fm/8vMho), the time appears to be right for Star Mountain to push forward in capitalizing on its promising mining operations. Look for the company to leverage the expertise of its proven management team and a strengthened cash position as it progresses toward recommencement of mining operations at the Balmat Mine in the near future.

For more information, visit www.starmountainresources.com

Let us hear your thoughts: Star Mountain Resources Inc. Message Board

Before the opening bell, OurPet’s Company (OTCQX: OPCO) announced a patent infringement settlement with Van Ness Plastic Molding Co., Inc. In the previously filed suit, OPCO alleged that Van Ness’ stainless steel, rubber-bottomed bowls infringed upon the company’s 529 utility patent, which covers a feeding dish with rubber on the bottom where the rubber does not extend up a sidewall. According to the news release, the matter was settled favorably to OurPet’s.

“We are pleased with the outcome of this patent infringement case,” Dr. Steve Tsengas, president and chief executive officer of OPCO, stated in this morning’s news release. “In the future, OurPet’s will continue to protect the value of our innovative product lines, and specifically our intellectual property portfolio, which currently includes 160 patents issued or pending.”

The intellectual property in question covers the company’s DuraPet® line, which is the leading line of pet dishes in the pet industry. According to the product’s description on Amazon (NASDAQ: AMZN), the OurPet’s DuraPet® Bowl uses a permanently-bonded rubber ring on the bottom of the bowl to prevent sliding and reduce noise while the pet is eating. The stainless steel bowl is scratch-resistant and crack-proof, and the product is dishwasher-safe for easy cleaning.

Over the years, OPCO has developed an expansive line of innovative pet products, including a strong IP portfolio featuring 160 issued or pending patents in the United States. In addition to its steadfast commitment to driving innovation in the pet industry, the company has committed significant effort to enforcing its patents against copycat competitors. These efforts have helped OPCO maintain a sizable and growing presence in the pet industry, as demonstrated by the company’s latest financial results.

In the fourth quarter of 2015, OPCO recorded $450,592 in net income, an increase of 10 percent from the same period in 2014. Likewise, the company’s 2015 full-year net income was up 74 percent over the results from the prior year, with OPCO continuing to benefit from specific management initiatives that resulted in lower fixed costs, lower production costs and lower general and administrative expenses. Following the successful implementation of its dual branding strategy, by which OPCO markets the OurPet’s brand for the pet specialty channel and the Pet Zone brand for the food, drug and mass retail channels, the company is well-positioned to build on these results and continue its positive momentum throughout the first quarter of 2016 and beyond.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

A biotechnology company, Nutra Pharma Corporation (OTCQB: NPHC) focuses on acquiring, licensing, and commercializing pharmaceutical products and technologies. The company concentrates on preventing and treating neurological disorders, cancer, and autoimmune and infectious diseases. Currently, Nutra Pharma offers Nyloxin® and Nyloxin® Extra Strength, the only non-narcotic and non-addictive treatments for severe pain that are sold over-the-counter. The company also markets Pet Pain-Away, an over-the-counter pain reliever for beloved pets. Furthermore, its multiple sclerosis and HIV applications are ready to move into phase II clinical trials. Through its two wholly-owned subsidiaries, Designer Diagnostics and ReceptoPharm, Nutra Pharma has already been able to contribute to the biopharmaceutical field in tremendous ways.

ReceptoPharm, the “drug discovery arm” for Nutra Pharma, develops therapeutic protein products that help prevent and treat viral, autoimmune, and neurological diseases in humans. For these products, the company focuses on receptor-binding proteins found in nature, specifically cobra venom. The two leading products created by ReceptoPharm are RPI-MN and RPI-78M. The first hinders neurological damaging viruses like encephalitis and HIV. The second treats neurological disorders like multiple sclerosis and adrenomyeloneuropathy. Both of these products are easily administered, stabilized, and cause no severe side effects.

Established in 2005, Designer Diagnostics develops and markets test kits that can identify harmful disease-causing bacteria quickly. This early detection allows doctors to administer treatments immediately to prevent the spreading of disease. The company’s diagnostic tests can detect harmful nontuberculous mycobacteria, which can lead to tuberculosis, nocardia, pseudomonas, and mycobacterium avium complex. Fortunately, these tests can detect diseases in less than a week, have a long shelf life, and can be stored in almost any environment. Plus, they are cost-effective and can integrate easily with any laboratory, which makes prevention both feasible and accessible.

Nutra Pharma, backed by its subsidiaries, aims to deliver bio-pharmaceutical breakthroughs that proactively increase the quality of life of people with debilitating diseases. By continuing its business model of acquiring biotechnological companies with similar goals and interests, the company stands to make an enormous impact in the pharmaceutical industry.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

A recent report labelled Progress Toward Sustainable Energy (http://dtn.fm/tU0nk) published the findings of energy experts from 15 agencies under the leadership of the World Bank and the International Energy Agency (IEA). The report cast a global spotlight that showed there are large swaths of the world without electricity. The report was also a good reminder of the world of opportunity that lies before the Dominovas Energy Corporation (OTCQB: DNRG) with its solid oxide fuel cell (SOFC) technology known as the RUBICON™.

According to Progress Toward Sustainable Energy just 94 percent of the urban population and 82 percent of the rural population in the Philippines have electricity. The report goes on to offer another reason why Africa might be termed the ‘Dark Continent’. In Angola, just 83 percent of the urban population and 6 percent of the rural population have electricity. In Kenya, it’s 58 percent and 7 percent, respectively. In Liberia, the numbers are 19 percent and 1 percent. Asia is brighter. China is on par with the developed world. Both in town and country, the Chinese have access to electricity. However, in Afghanistan, just 83 percent of town dwellers and 6 percent of country folk have electricity. In Bangladesh, it’s 90 percent for the town and 49 percent for the country. In India, just 70 percent of the rural population has access to electricity.

The Indian story India’s Energy Crisis (http://dtn.fm/M2Me0) was told in MIT Technology Review. ‘At least 300 million of India’s 1.25 billion people live without electricity… Another quarter-billion or so get only spotty power from India’s decrepit grid, finding it available for as little as three or four hours a day. The lack of power affects rural and urban areas alike, limiting efforts to advance both living standards and the country’s manufacturing sector.’

The Dominovas Energy Corporation’s solid oxide fuel cell (SOFC) technology, RUBICON™, is certainly up to the challenge of bringing light to the world. The RUBICON™ is fuel flexible and capable of reforming multiple fuels such as natural gas, propane, LPG, diesel, landfill gas and flare gas. Reforming is a process of extracting the hydrogen used in the fuel cell from hydrocarbon fuels. Although hydrogen is the most abundant element in the universe, in its elemental form it exists on Earth only in the smallest of quantities.

The RUBICON™ is ideal for distributed power generation and operation at multi-MW levels in frontier markets, given the flexibility of its use and its ability to function in a grid scenario or through independent, isolated, “island” operations.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

An innovative leader in the pet industry, OurPet’s Company (OTCQX: OPCO) aims to improve the health, safety, and comfort of household pets while ensuring they’re having fun with their owners. The company first stepped into the pet space in 1995, when the industry was pulling in $16 billion in annual sales. According to the American Pet Products Association (APPA), that number is now $65 billion. Cat products alone are increasing by 6% each year. OurPet’s is aiming to capitalize on this trend and climb to $50 million in annual sales in the next five years. To do this, the company has been continuously updating its infrastructure to meet its goals.

First, OurPet’s developed a new branding strategy in 2012 that easily segregates its products into two brands targeting different market segments. The OurPets® Brand is a high-end product brand that caters to pet specialty stores like PetSmart, Petco, and Pet Valu. This line consists of patented one-of-a-kind products such as the Whirling Wiggler™, a butterfly-inspired toy that simulates insect movement for cats, and the Flappy® Chirp-N-Prey™, a squeaky toy that promotes healthy gums and teeth for dogs.

The company’s second product line, PetZone®, markets affordable pet products to food, drug, and mass retailers like Wal-Mart (NYSE: WMT), Kroger (NYSE: KR), and Amazon (NASDAQ: AMZN). Consumers will find products such as toys, feeding solutions, waste management solutions, and accessories at these stores. The PetZone brand boasts “specialty quality products at affordable prices.”

Furthermore, over the past three years, OurPet’s has been expanding its management team into a company stronghold that delivers experience and expert knowledge. For example, the company added Gabriella Chessman as vice president of marketing, Kathleen Peters-Homyock as vice president of sales, Scott Mendes as chief financial officer, and Dean Tsengas as chief operating officer.

Lastly, OurPet’s updated its Enterprise Resource Planning (ERP) system with warehouse logistics. Now it can receive all orders electronically all the way to payment. This change allows for a faster and more efficient ordering process that can promote more revenue along with heightened customer satisfaction.

With constant reevaluation of the company framework, OurPet’s is positioned to maintain its leadership status in the pet industry. By creating 160 individual patents that have no equal, the company stands by its intentions of exceeding the expectations of pets and their owners.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Halitron, Inc. (OTC: HAON) is an equity holding company that focuses on acquiring sales, marketing, and manufacturing businesses and weaving their assets into its existing infrastructure. The company acquires bankrupt, distressed and insolvent companies inexpensively. HAON also acquires profitable companies at a multiple of earnings ranging from two to four times, before the deduction of interest, tax and amortization expenses (EBITDA).

As an example, NDG Holdings, Inc., acquired in 2015, has been a service oriented company providing digital marketing services such as website development, email blasts, SEO, and PPC management, among others. Over time, management expectations are to use its infrastructure and intellectual capital in order to become more vertically integrated by acquiring manufacturing based businesses which will improve gross margins. This strategic process will give management the flexibility to compete more effectively and invest at a greater rate within its business.

Halitron, Inc. is guided by chief executive officer Bernard Findley, who for the last two decades has been working with small- to mid-size businesses. Early in his career, with the majority of his involvement being with growth opportunities, Findley would build up sales and then sell. Later in his career, Findley was engaged in orchestrating a roll-up of 16 bankrupt, insolvent, and distressed brands.

Understanding that growth initiatives are very different than turnaround work, Findley gained insight into how to take advantage of strengths within a business, reshape the business plan, and then execute on the deliverables. He has worked in industries focused on medical devices, direct marketing and promotional products. Since 2011, he has rolled up and exited 16 brands that would have likely remained distressed or bankrupt without his guidance. Today, these brands exist and are operating under new owners.

Halitron, Inc. was formerly known as Teknik Digital Arts, Inc. and changed its name to Halitron, Inc. in August 2014. The company was founded in 2003 and is based in Newtown, Connecticut, with a location in San Diego, California.

For more information, visit www.halitroninc.com

Let us hear your thoughts: Halitron, Inc. Message Board

A leading international family entertainment and media company, Agora Holdings, Inc. (OTC: AGHI) delivers innovative experiences to TV, studio entertainment, consumer products, interactive media, and media networks. Through wholly-owned subsidiary GeegLe Media, the holding company aims to fill the needs of social media, TV, data storage applications, and other software solutions.

GeegLe Media, which operates under its domain name, Geegle.TV, created its own Video on Demand platform, which combines radio, news, sports, and kids content. The subsidiary announced in July 2015 that its new services include new custom channels for various users. The first customizable channel is for freelancers and content producers to market themselves. The second is for real estate brokers to create their own channels to expand marketing capabilities. Using GeegLe Media’s customized real estate channel, clients can tour residential and commercial investment properties right from their homes.

That same month, Geegle.TV built a software capable of filtering third party content, such as YouTube videos, for higher quality. This software integration allows the company to curate content from the world’s largest video selection. Agora Holdings also announced its partnership with high schools throughout Ontario in developing a video creation platform for students. Through this platform, students can create and upload videos to share with people in their school networks, which utilizes their already advanced computer skills in a positive way.

In September, 1000salads, a division of GeegLe Media that offers nutritional information, announced plans to add an e-commerce store in which consumers can purchase healthy foods and products. Agora Holdings is also working on releasing its Real TV project later this year. This platform is designed for real estate professionals to market their properties through customer interaction. Clients can use editing and voiceover tools to customize video content to reach a wider audience. The real estate industry relies heavily on advertising, making this platform highly favorable to investors.

GeegLe Media completed its TECH workflow system in November, which simplifies assignments while increasing efficiency in the workplace. Companies can receive, accept, and assign orders without the hassles of paperwork. Plus, these companies can better manage productivity, accountability and performance.

Agora Holdings intends on bringing the “best entertainment and online experiences” to the world. The company will continue expanding its brand while creating and improving its products. By creating relevant products that capitalize on industry trends, Agora Holdings aims to maximize revenue for its shareholders and investors.

For more information, visit www.agoraholdingsinc.com

Let us hear your thoughts: Agora Holdings, Inc. Message Board

Most people are surprised to find out that two types of herpes viruses — the one that causes cold sores and the one that causes chickenpox — can cause a condition called herpetic eye disease. Unlike a separate virus that causes genital herpes, herpetic eye disease is not sexually transmitted.

The recent presentation by the CEO of NanoViricides, Inc. (NYSE MKT: NNVC), Eugene Seymour MD, MPH, at Biotech Showcase 2016 illustrated how the company is currently moving full speed ahead with human trials for its lead virucidal herpes (of the eye/cornea) keratitis (inflammation of the cornea) treatment, HerpeCide™. Human clinical trials are currently on-track to begin late this year or in early 2017, and commercially-available HerpeCide would be a most welcome addition to the healthcare system’s existing biomedical arsenal, as ocular herpetic disease in general is a serious challenge for both optometrists and patients.

Herpes keratitis is the leading cause of infectious blindness in the Western world and ultimately requires a corneal transplant when it has progressed to the stage of blindness. Corneal transplant is a difficult procedure that can often fail and the procedure can cost as much as $24,400 on average, according to actuarial intelligence giant Milliman. The major herpes viruses that cause ocular disease (simplex and zoster) quite often bring about immunologic reactions in the host that outlive any active infection as well, meaning that the latent demand for a real solution is considerably larger than the baseline market metrics would indicate.

One of the viruses that causes herpetic eye disease is called the varicella-zoster virus. It is the same virus that causes chickenpox and shingles. When this virus affects the eye, it is called herpes zoster ophthalmicus.

Herpes keratitis is a viral infection of the eye caused by the herpes simplex virus (HSV). There are two major types of the virus. Type I is the most common and primarily infects the face, causing the familiar “cold sore” or “fever blister.” Type II is the sexually transmitted form of herpes, infecting the genitals.

The combined estimated market size for NanoViricides’s antiviral eye drops designed to fight conjunctivitis/keratitis, its HerpeCide™ indication for shingles, as well as ocular and genital herpes (note that HSV-1 has also been linked to Alzheimer’s), and its DengueCide™ indication to combat Dengue arboviruses (West Nile, Yellow Fever, Japanese B Encephalitis), are in the neighborhood of $17 billion.

While both Type I and Type II herpes can spread to the eye and cause infection, Type I is by far the most frequent cause of eye infections. Infection can be transferred to the eye by touching an active lesion (a cold sore or blister) and then your eye.

Type I herpes is very contagious and is commonly transmitted by skin contact with someone who has the virus. Almost everyone — about 90 percent of the population — is exposed to Type I herpes, usually during childhood.

After the original infection, the virus lies in a dormant state, living in nerve cells of the skin or eye. Reactivation can be triggered in a number of ways, including: stress; sun exposure; fever; trauma to the body (such as injury or surgery); menstruation; and certain medications.

Once herpes simplex is present in the eye, it typically infects the eyelids, conjunctiva (the thin, filmy, mucous membrane that covers the inside of the eyelids and the white part of the eye) and cornea (the clear, front window of the eye). It may also infect the inside of the eye; however, this is much less common. The symptoms of herpes keratitis may include pain, redness, blurred vision, tearing, discharge and sensitivity to light.

If the infection is superficial, involving only the cornea’s outer layer (called the epithelium), it will usually heal without scarring. However, it if involves the deeper layers of cornea (which can happen after time), the infection may lead to scarring of the cornea, loss of vision and sometimes even blindness. Left untreated, herpes keratitis can severely damage your eye.

NanoViricides recently entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides® drug candidates in standard animal models of ocular virus infections. Dr. Eric Romanowski, research director, will perform the research in the Charles T. Campbell Ophthalmic Microbiology Laboratory. Dr. Romanowski has extensive experience in ocular virus infections and anti-viral agents discovery.

These animal studies will evaluate the efficacy and potency of the company’s nanoviricides anti-viral agents in ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of ocular herpes keratitis in humans.

“We are very pleased to have the Campbell Laboratory join our efforts in developing a drug against Herpes Keratitis,” Eugene Seymour, MD, MPH, CEO of NanoViricides, stated in a recent news release, adding, “This is a renowned lab in the field of ocular infections with substantial experience in antiviral drugs development. We plan to perform IND-enabling efficacy studies of our anti-viral agents at the Campbell Labs.”

The Charles T. Campbell Ophthalmic Microbiology Laboratory is part of the University of Pittsburgh Medical Center’s Eye Center (UPMC Eye Center). The UPMC Eye Center in the Department of Ophthalmology of the University of Pittsburgh School of Medicine has one of the top basic and clinical research programs in the country. UPMC Eye Center’s research focuses on infectious disease, ocular immunology, molecular genetics and molecular biology of retinal disease, glaucoma and advanced diagnostic imaging technology development.

For more information, please visit the company’s website at www.nanoviricides.com